Open Access<p>Arsenic Disulfide Promoted Hypomethylation by Increasing DNA Methyltransferases Expression in Myelodysplastic Syndrome</p>
Author(s) -
Qi Zhou,
ZhengTang Liu,
Hongzhi Wang,
Xiaoqing Guo,
Yan Xu,
Xiaomei Hu
Publication year - 2020
Publication title -
drug design, development and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.964
H-Index - 64
ISSN - 1177-8881
DOI - 10.2147/dddt.s239158
Subject(s) - methyltransferase , dna methylation , methylation , dnmt3b , myelodysplastic syndromes , microbiology and biotechnology , dnmt1 , biology , cancer research , gene expression , gene , bone marrow , genetics , immunology
Previous studies have shown that DNA methylation plays a significant role in myelodysplastic syndrome (MDS). In addition to hypermethylation, aberrant hypomethylation can result in the transcriptional activation of oncogenes in cancer, including MDS. Therefore, drugs targeting DNA hypomethylation are needed for the treatment of MDS. This study aimed to investigate whether As 2 S 2 promoted hypomethylation by increasing DNA methyltransferases (DNMTs) expression in MDS.